|
Squamous cell carcinoma of the head and neck
|
0.300 |
Biomarker
|
disease |
CTD_human |
Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells.
|
29464035 |
2018 |
|
Malignant mesothelioma
|
0.300 |
Biomarker
|
disease |
CTD_human |
MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion.
|
25756049 |
2015 |
|
Endometriosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis.
|
20864642 |
2011 |
|
Polycystic Ovary Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Endometrioma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis.
|
20864642 |
2011 |
|
Sclerocystic Ovaries
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Finally, 12 upregulated hub genes (TOP2A, MAD2L1, FEN1, EPRS, EXO1, MCM4, PTTG1, RRM2, PSMD14, CDKN3, H2AFZ, CCNE2) and 3 downregulated genes (FGF2, BCL2, PIK3R1) contributed to significant unfavorable clinical outcome in breast cancer (p<0.05).
|
31777591 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
The KCNQ1OT1/miR-145/CCNE2 axis plays a critical regulatory role in BRCA, potentially giving rise to BRCA tumorigenesis and progression.
|
30157476 |
2018 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.
|
26265440 |
2015 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this work, we demonstrate that stimulation of hERG1 promotes an ubiquitin-proteasome-dependent degradation of cyclin E2 in multiple breast cancer cell lines representing Luminal A, HER2+ and Trastuzumab-resistant breast cancer cells.
|
25596745 |
2015 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The results of this study suggest that luteolin can be used as a chemosensitiser to target the expression level of CCNE2 and that it could be a novel strategy to overcome TAM resistance in breast cancer patients.
|
23790951 |
2013 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Among these oncogenes, TSPYL5 and CCNE2 have been already known as prognostic biomarkers in breast cancer, CD55 has been suspected of playing an important role in breast cancer prognosis from literature evidence, and other three genes are newly discovered breast cancer biomarkers.
|
24073403 |
2013 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the effect of the expression of these 2 proteases in addition to 2 potential intracellular targets of NE (CCNE1 and CCNE2) on clinical outcome in a population of 205 primary breast cancer patients.
|
16929516 |
2006 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The second E-type cyclin, cyclin E2, has been shown to be overexpressed in breast cancers although the potential role as a diagnostic or prognostic marker is unknown.
|
14510182 |
2003 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The increased level of cyclin E2 in breast tumors suggests that, similar to cyclin E1, it may contribute to the pathogenesis of breast cancer.
|
12466974 |
2002 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Finally, 12 upregulated hub genes (TOP2A, MAD2L1, FEN1, EPRS, EXO1, MCM4, PTTG1, RRM2, PSMD14, CDKN3, H2AFZ, CCNE2) and 3 downregulated genes (FGF2, BCL2, PIK3R1) contributed to significant unfavorable clinical outcome in breast cancer (p<0.05).
|
31777591 |
2019 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
The KCNQ1OT1/miR-145/CCNE2 axis plays a critical regulatory role in BRCA, potentially giving rise to BRCA tumorigenesis and progression.
|
30157476 |
2018 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.
|
26265440 |
2015 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
In this work, we demonstrate that stimulation of hERG1 promotes an ubiquitin-proteasome-dependent degradation of cyclin E2 in multiple breast cancer cell lines representing Luminal A, HER2+ and Trastuzumab-resistant breast cancer cells.
|
25596745 |
2015 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The results of this study suggest that luteolin can be used as a chemosensitiser to target the expression level of CCNE2 and that it could be a novel strategy to overcome TAM resistance in breast cancer patients.
|
23790951 |
2013 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Among these oncogenes, TSPYL5 and CCNE2 have been already known as prognostic biomarkers in breast cancer, CD55 has been suspected of playing an important role in breast cancer prognosis from literature evidence, and other three genes are newly discovered breast cancer biomarkers.
|
24073403 |
2013 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the effect of the expression of these 2 proteases in addition to 2 potential intracellular targets of NE (CCNE1 and CCNE2) on clinical outcome in a population of 205 primary breast cancer patients.
|
16929516 |
2006 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The increased level of cyclin E2 in breast tumors suggests that, similar to cyclin E1, it may contribute to the pathogenesis of breast cancer.
|
12466974 |
2002 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Initial findings indicated that CcnE1 and CcnE2 have largely overlapping functions for cancer development in several tumor entities including hepatocellular carcinoma (HCC).
|
30150405 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Initial findings indicated that CcnE1 and CcnE2 have largely overlapping functions for cancer development in several tumor entities including hepatocellular carcinoma (HCC).
|
30150405 |
2018 |